Gossamer Bio Inc (NAS:GOSS)
$ 0.6833 -0.0107 (-1.54%) Market Cap: 154.57 Mil Enterprise Value: 121.66 Mil PE Ratio: 0 PB Ratio: 5.69 GF Score: 38/100

Gossamer Bio Inc To Discuss Phase 2 SHIFT-UC Topline Clinical Trial Results Call Transcript

Apr 25, 2022 / 12:30PM GMT
Release Date Price: $9.08 (+3.18%)
Operator

Good day, and thank you for standing by. Welcome to the Gossamer Bio Incorporated Update Call. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Mr. Bryan Giraudo, Chief Financial Officer and Chief Operating Officer. Sir, please go ahead.

Bryan Giraudo
Gossamer Bio, Inc. - COO & CFO

Thank you, operator, and thank you all for joining us this morning. I'm joined today by Gossamer Bio's Co-Founder, Chairman and Chief Executive Officer, Faheem Hasnain; our Chief Medical Officer, Dr. Richard Aranda; Gossamer's Executive Director of Clinical Development and the Clinical Development Lead for the GB004 program, Dr. Barrett Levesque; as well as Gossamer's Vice President of Biostatistics and the Biostatistics Lead for the GB004 program, Kartik Raghupathi.

Earlier this morning, Gossamer Bio issued a press release announcing the GB004 Phase II SHIFT-UC top line results. Please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot